Epirus, Ranbaxy win India approval for arthritis drug copy

September 15, 2014 8:01 PM

4 0

Epirus, Ranbaxy win India approval for arthritis drug copy

(Reuters) - Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

The company's Indian partner, Ranbaxy Laboratories Ltd, will sell a copycat version of Johnson & Johnson's and Merck & Co Inc's infliximab, an anti-inflammatory drug with annual sales of about $6 billion.

Read more

To category page

Loading...